Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women

Rebecca L. Sedjo, Paula Inserra, Martha Abrahamsen, Robin B. Harris, Denise J. Roe, Susie Baldwin and Anna R. Giuliano
Rebecca L. Sedjo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Inserra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martha Abrahamsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin B. Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise J. Roe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susie Baldwin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna R. Giuliano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Persistent oncogenic human papillomavirus (HPV) infection is associated with cervical dysplasia. Cofactors, such as nutrient status, may be required for the progression of HPV infection to neoplasia. HPV DNA methylation patterns in vitro have been shown to be associated with viral transcriptional activity. Folate, vitamin B12, vitamin B6, and methionine may function to prevent cervical cancer through their role in DNA methylation. This study was conducted to examine the relationship of dietary intake of folate, vitamin B12, vitamin B6, and methionine, as well as circulating levels of folate and vitamin B12 to HPV persistence. Oncogenic HPV status was determined at baseline and at ∼3 and 9 months postbaseline. Multivariate logistic regression analysis was used to determine the adjusted odds ratios for persistent HPV infection associated with each tertile of individual nutrient among 201 women with a persistent or intermittent HPV infection. Circulating vitamin B12 levels were inversely associated with HPV persistence (P for trend, 0.037) after adjusting for age, age at first intercourse, marital status, cigarette smoking status, race, and body mass index. In addition, women with circulating levels in the highest tertile (>493.2 pg/ml) of vitamin B12 were less likely to have a persistent infection (adjusted odds ratio = 0.4; 95% confidence interval = 0.17–0.96). No significant associations were observed between HPV persistence and dietary intake of folate, vitamin B12, vitamin B6, or methionine from food alone or from food and supplements combined or from circulating folate. These data suggest a role for circulating vitamin B12 in early cervical carcinogenesis.

Introduction

Cervical cancer is the third leading cause of cancer in women, comprising 9.8% of new cancer cases worldwide (1) . Infection with oncogenic HPVs3 has been shown to be the primary etiological factor for cervical cancer (2, 3, 4) , as well as its precursor lesion, cervical intraepithelial neoplasia (5, 6, 7) . HPV infections are often transient (8 , 9) , but persistent infections, especially with oncogenic HPV types, can further increase the risk of cervical dysplasia (5 , 6 , 10 , 11) . Although HPV infection is essential for cervical cancer, not all women infected with the virus progress to invasive cervical cancer. Nutritional factors may contribute to the progression of HPV infection to neoplasia (12) .

In vitro evidence indicates that HPV DNA methylation patterns are associated with viral transcriptional activity (13) . Methylation of the upstream regulatory region of HPV has been shown to prevent transcription in vitro, suggesting that methylation can decrease viral proliferation (14) . Folate, as well as vitamins B12 and B6, may function to prevent cervical cancer through their role in DNA methylation as they contribute to the synthesis of S-adenosylmethionine (15 , 16) , the primary donor for the methylation of DNA and RNA (17) .

Despite compelling biochemical evidence for a role of folate and vitamin B12, the epidemiological literature has not supported an association with cervical neoplasia. Case control studies assessing dietary folate intake have not shown a protective effect against cervical dyplasia (18, 19, 20, 21) , carcinoma in situ (22 , 23) , or invasive cervical cancer (24, 25, 26) .

Furthermore, of the five case control studies that assessed the association between cervical dysplasia and circulating folate concentrations (18 , 20 , 27, 28, 29) , only two reported a protective effect (18 , 27) . Similarly, higher circulating concentrations of folate were not protective against invasive cervical cancer (30, 31, 32) . Two investigations assessed circulating vitamin B12 levels, but neither observed an association between cervical dysplasia (28) and cancer (30) . Finally, three clinic trials of folic acid supplementation were conducted among women with cervical dysplasia (33, 34, 35) . Only one of these trials resulted in cytological improvement (33) .

As the majority of epidemiological studies that assessed the association between methyl donor nutrients and risk of cervical neoplasia did not include measures of HPV status, these studies must be interpreted with caution. No previous investigation has evaluated the association between folate, vitamin B12, vitamin B6, and methionine and the early carcinogenic event of HPV persistence. Therefore, this study was conducted to test whether increased dietary intake of folate, vitamin B12, vitamin B6, or methionine, or circulating levels of folate or vitamin B12, are associated with decreased risk of HPV persistence.

Materials and Methods

The Young Women’s Health Study was a prospective cohort study designed to investigate the natural history of HPV infections among healthy women. Study visits occurred at baseline and ∼3- and 9-months postbaseline. The University of Arizona’s Human Subjects Committee approved this study protocol. Before study entry, all participants signed an informed consent form.

Subjects.

From September 1996 to August 1999, all healthy women receiving routine gynecological care at a reproductive health care clinic were approached by a study interviewer for participation in the Young Women’s Health Study. Of the 1950 women approached, 1541 women met the eligibility criteria, and 1342 women were enrolled in the baseline visit. Eligibility criteria included being aged 18–35 years, currently sexually active or seeking birth control, resident of the Tucson metropolitan area, no treatment for cervical intraepithelial neoplasia within the last 18 months, no abnormal Pap smear in the last 18 months, no history of chronic illness, not currently pregnant and >2 months postpartum, still having menstrual periods (i.e., no hysterectomy), and no relocation plans over the next 12 months. At the baseline visit, each participant completed an extensive self-administered questionnaire regarding socio-demographics, cigarette smoking history, sexual behaviors, and reproductive history. During each participant’s routine gynecological examination, exfoliated cells for HPV analysis were collected after Pap smear sample collection.

A group of 822 women (61%) who completed the baseline visit and had a baseline Pap smear of negative or atypical squamous cells of undetermined significance were invited to participate in the follow-up visits. Women, who were positive for any one of 13 oncogenic HPV types or HPV negative at baseline, were recruited to the follow-up visits. Women who were HPV negative were included in the study as they were at risk for acquiring an HPV infection over the study period. Groups of 346 and 206 women completed scheduled 3- and 9-month study visits, respectively. Of the 346 women who completed at least one follow-up visit, 187 (54%) were positive for an oncogenic HPV infection at baseline, and the remaining were HPV negative. Cytology and HPV testing were performed as part of each follow-up gynecological examination. Participants were monetarily compensated ($50) for participation in each of the follow-up visits. Women completing follow-up visits were more educated (P = 0.05) and less likely to be current smokers (P < 0.01) than women completing the baseline visit only; however, there were no significant differences in age, race, marital status, age at first intercourse, number of sexual partners, parity, oral contraceptive use, and ever having a Pap smear (data not shown).

HPV Analysis.

HPV status at the baseline and follow-up visits was determined using Hybrid Capture II (Digene Corp, Beltsville, MD) to detect oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Positive samples were defined as a ratio of greater than 1 RLU of sample divided by RLUs of a positive control. Repeat testing was conducted on samples with equivocal readings (range 1–2 RLUs) with results of ≥1 RLU classified as positive. Samples with repeated values <1 RLU were analyzed a third time and classified based on the results of the two concordant results. Approximately, 1 pg of viral DNA/ml sample can be detected by this method (36) .

Because the objectives of this investigation were to test the association of nutrients involved in methylation with HPV persistence, only participants who tested positive for an HPV infection and had at least one follow-up visit were included in this analysis. HPV persistence was defined as women who were HPV positive for any oncogenic HPV infection at two or more consecutive time points (n = 131), whereas women who were positive for any oncogenic type infection at one or more nonconsecutive time points were classified as having intermittent infections (n = 70). Women who tested negative for HPV until the last clinic visit, and then tested positive (n = 24), and women who were consistently HPV negative (n = 121) were excluded from these analyses.

Dietary Intake Analysis.

Trained interviewers administered the AFFQ at the 3-month visit. The AFFQ is a modification of the dietary portion of the Block National Cancer Institute Health Habits and History Questionnaire (37) and includes foods common to the Southwestern United States (i.e., salsa and burritos), as well as low-fat food items. Vitamin supplement duration, dosage, and brand are included. This optically scannable, semiquantitative questionnaire measured participants’ usual intake by asking questions regarding the frequency and portion size of 153 food items over the previous 3 months. The validity and reliability of this questionnaire have been investigated through comparisons with four 24-h food recalls, as well as repeated administration after 1 year of both AFFQ and four 24-h recalls (38) or four dietary records (39) in two different prospective studies.

Nutrient values were calculated from the participants’ reported dietary and supplement intake using a database derived from the 1994 USDA Food Composition Database, the USDA Continuing Survey of Food Intake of Individuals 1994–1996 and 1998, and the Nutrient Database for Standard Reference (version 11–13). To capture the additional folate intake because of fortification of enriched grain products, mandated by the United States Food and Drug Administration as of January 1, 1998 (40) , two databases were used. Questionnaires completed on or after January 1, 1998 were analyzed from the database, which included fortified grain products, whereas questionnaires completed before this date were analyzed without the updated fortification values. A group of 140 participants completed the AFFQ before January 1, 1998, and 206 participants completed the AFFQ after this date. All dietary calculations used age-specific portion sizes for women. From these databases, semiquantitative nutrient intake values were obtained for folate, vitamin B12, vitamin B6, and methionine.

Circulating Folate and Vitamin B12 Measures.

At the 3- and 9-month clinic visits, fasting blood samples were collected by venipuncture using Monoject evacuated tubes containing EDTA (Sherwood Medical, St. Louis, MO) for quantitative assessment of circulating nutrient values. All samples were separated, and the resulting plasma aliquots were stored at −80°C until analyses were conducted.

Plasma samples were obtained from 285 participants, 82% who completed the 3-month study visit, and 180 participants, 87% who completed the 9-month study visit. Twenty women completed both the 3- and 9-month visits, but blood was obtained only at the 9-month visit. The most common reasons for not obtaining blood (n = 41) were that the phlebotomist was unable to find a vein (n = 29), only a small amount of blood was obtained (n = 8), or the participant refused (n = 4). Participants with and without samples were comparable on age, race, education, marital status, cigarette smoking, and BMI.

Plasma folate and vitamin B12 were quantified in duplicate using the Quantaphase II B12 and Folate Radioassay (Bio-Rad Laboratories, Inc., Hercules, CA). To minimize interference because of EDTA, plasma samples were filtered using serum filter columns (Image Molding, Denver, CO) before analysis. On the basis of repeated measurements of a pooled plasma sample, the interassay coefficient of variation was 13% for plasma folate and 0.41% for plasma vitamin B12.

The average of two plasma values was used unless only one sample was available, in which case, the single value was used. Overall, 60 (86%) participants with intermittent infections and 109 (83%) participants with persistent infections had available plasma samples for analysis. The Pearson correlation coefficients of log-transformed 3- and 9-month nutrient levels were significant at r = 0.45 (P < 0.01) for folate and r = 0.42 (P < 0.01) for vitamin B12 among participants with both measures. Although at least one plasma sample was available for 298 participants, only participants who had an intermittent or persistent HPV infection were included in the statistical analyses (n = 170). Because of a single inadequate sample, 169 participants had samples available for folate analysis.

Statistical Analysis.

To test whether increased dietary intake levels of nutrients involved in the methylation pathway were associated with decreased HPV persistence, two groups were compared: women with persistent infections (n = 131) and women with intermittent infections (n = 70). Nutrient intake and plasma levels were categorized into tertiles based on the distribution of the intermittent group. Bivariate analyses were conducted for age, race, education, marital status, cigarette smoking history, age at first intercourse, lifetime number of sexual partners, parity, number of pregnancies, oral contraceptive use, Depo Provera use, and Pap smear history, as well as variables that would account for under and over-reporting of dietary intake, such as BMI and total energy intake. χ2 analyses for categorical variables and two sample t tests or ANOVAs for continuous variables were used. Non-nutrient risk factors associated with both HPV persistence and any dietary or plasma nutrient at P ≤ 0.2 were assessed in multivariate logistic regression models. To maximize statistical power, only those variables associated with both nutrient status and HPV persistence were retained as covariates using multivariate analysis. Backwards stepwise elimination was performed, and only significant variables at P < 0.05 (age at first intercourse, marital status, race, and BMI) were retained in the final model. Age and cigarette smoking (P = 0.052) were also included in the model to be consistent with the literature. Because of the high intercorrelation of the nutrients, risk of HPV persistence was estimated individually for each nutrient. Multivariate logistic regression modeling of HPV persistence was performed to obtain an estimate of the association (adjusted OR) and 95% CIs. Treating categorical nutrient variables as continuous variables in multivariate logistic regression allowed for the assessment of linear trends. Pearson correlation coefficients were estimated between circulating and dietary nutrient levels using the log-transformed values as these data were highly skewed. All statistical tests performed were two sided with an α level of 0.05 and were performed using Intercooled STATA (2001 Stata Statistical Software: Release 7.0; StataCorp., College Station, TX).

Results

The unadjusted mean values of dietary intake and circulating nutrient levels for participants with intermittent and persistent HPV infections are reported in Table 1⇓ . No significant differences were observed in dietary intake from food alone or food and supplements combined for folate, vitamin B12, vitamin B6, and methionine among participants with persistent HPV infections and participants with intermittent HPV infections. Circulating folate and vitamin B12 levels were equivalent when participants with persistent and intermittent HPV infections were compared.

View this table:
  • View inline
  • View popup
Table 1

Unadjusted meana values of dietary intake and circulating nutrient levels by case control status

Dietary folate, vitamin B12, vitamin B6, and methionine intakes from food sources were highly intercorrelated, e.g., a correlation coefficient of r = 0.92 (P < 0.01) was observed between dietary folate and vitamin B6. The high correlation coefficients were likely because of fortification of these nutrients simultaneously in certain foods, such as fortified breakfast cereals, which were reported frequently by study participants. In this cohort, the correlations between dietary nutrients from foods and circulating folate and vitamin B12 concentrations were low; r = 0.10 (P = 0.21) for folate and r = 0.15 (P = 0.18) for vitamin B12. Eighty-three (41%) women consumed vitamin supplements of folate, vitamin B6, and B12. The correlations between dietary nutrients and their plasma concentrations remained low when nutrients from supplements were combined with food values; r = 0.23 (P < 0.01) for folate and r = 0.26 (P < 0.01) for vitamin B12.

The distributions of socio-demographic and cervical neoplasia risk factor characteristics by tertiles of dietary food intake and circulating measures are reported in Table 2⇓ . Race was significantly associated with dietary folate intake from food and circulating vitamin B12 concentrations, and energy was associated with both food folate and vitamin B12 intake. The oral contraceptive used was significantly associated with circulating vitamin B12 concentrations.

View this table:
  • View inline
  • View popup
Table 2

Distribution of socio-demographic and cervical neoplasia risk factor characteristics by tertiles of dietary intake and circulating measures among study participants

Table 3⇓ presents the association between specific dietary nutrients and HPV persistence. No significant associations were observed between HPV persistence and dietary folate, vitamin B12, vitamin B6, and methionine. Furthermore, no association was observed with HPV persistence when combined measures of food and supplement intake for folate, vitamin B6, or vitamin B12 were examined. Although not statistically significant, an inverse association was observed between dietary folate from food alone and HPV persistence. Among women consuming the highest level of folate from food sources, risk of HPV persistence was 0.52 (95% CI = 0.23–1.18).

View this table:
  • View inline
  • View popup
Table 3

Association between specific dietary micronutrient intake and HPV persistence, n = 201

Table 4⇓ presents the association between circulating nutrients and HPV persistence. No association was observed between HPV persistence and circulating folate levels. After adjustment, circulating vitamin B12 concentrations remained inversely associated with HPV persistence (P for trend, 0.037). Women with circulating levels in the highest tertile (>493.2 pg/ml) of vitamin B12 were significantly less likely to have a persistent infection (OR = 0.4; 95% CI = 0.17–0.96).

View this table:
  • View inline
  • View popup
Table 4

Association between circulating nutrients and HPV persistence

Discussion

Infection with persistent oncogenic HPV infection is the major risk factor for the development of cervical dysplasia (5 , 6 , 10 , 11) . In previous studies, folate, carotenoids, vitamin C, vitamin E, and retinols have been investigated as potential modifiers of cervical dysplasia and cancer risk (12) . The current study, however, is the first conducted to examine the association of nutrients involved in DNA methylation (i.e., folate, vitamin B12, vitamin B6, and methionine) and risk of HPV persistence. The findings from this investigation suggest that circulating vitamin B12 concentrations may be protective against HPV persistence. However, no significant reduction in HPV persistence risk was observed for dietary intake of folate, vitamin B12, vitamin B6, methionine from food alone, and food and supplements combined or for circulating concentrations of folate.

Most investigations of diet and cervical neoplasia have used a retrospective design and, therefore, were unable to measure HPV persistence. To our knowledge, no study has previously addressed the association between vitamin B12 and HPV persistence, although two previous studies have assessed circulating vitamin B12 concentrations in the prevention of cervical dysplasia (28) or cancer (30) . Goodman et al. (28) reported no association between circulating vitamin B12 concentrations and atypical squamous cells of undetermined significance and low-grade or high-grade squamous intraepithelial lesions. Differences in study findings may be because of dissimilarities in the racial distributions of cohorts, a factor known to influence food choices. In a nested case control study, no association was observed between serum vitamin B12 concentrations and carcinoma in situ or invasive cervical cancer (28) . However, this study assessed HPV-16 antibody status at baseline only and, therefore, could not assess other oncogenic HPV types.

In our population, high circulating vitamin B12 concentrations were protective against HPV persistence. One hypothesized mechanism by which vitamin B12 may protect against cervical carcinogenesis is through viral DNA methylation. DNA methylation plays a significant role in gene expression, DNA structural stability, and DNA damage and repair mechanisms (16 , 41) , all of which are believed to be important in preventing carcinogenesis. A randomized trial examining the effect of supplemental folate (42) , a methyl donor nutrient, among participants with colon adenomas reported that folate supplementation increased genomic methylation, suggesting that higher dietary consumption of certain nutrients may be protective through their influence on gene methylation status. In support of this hypothesis, a decrease in in vitro HPV transcription has been shown when the regulatory upstream region was methylated (13 , 14) , suggesting a role for methylation in preventing the maintenance of HPV infection.

It is also possible that circulating vitamin B12 is a surrogate marker for some other unmeasured factor that is protective against HPV persistence. In our study, circulating vitamin B12 concentrations and dietary intake measures were poorly correlated, which is consistent with a previous report from a similar population (43) . These poor correlations suggest that diet and circulating concentrations measure different exposures and may help to explain why a relationship between circulating vitamin B12 concentrations, but not dietary vitamin B12 intake, was observed in this study.

There are several strengths to consider when interpreting the results of this study. HPV status was determined with multiple measures of HPV infection over a 9-month period. This study measured both dietary intake and circulating measures of folate and vitamin B12, within the same woman. The database used to calculate folate nutrient values from the AFFQ was established to account for the addition of fortified grain products to the American diet, as determined by the completion date of the AFFQ.

As well, potential limitations need to be considered when interpreting the results from this study. Only 346 of women invited to the follow-up visits participated, thus limiting the power to detect statistically significant differences between groups. Because this study was conducted at only one clinic site, the results may not be generalizable to other populations. Although we were not able to assess type-specific oncogenic infections because of the molecular method used to detect HPV, the risk of cervical dysplasia has been shown to increase with either the same or different type oncogenic HPV persistence (6) . Therefore, HPV persistence with an oncogenic type, as determined in our study, provides a useful measure of subsequent cervical neoplasia risk. As with any study, assessing the dietary intake of folate is problematic as the dietary intake database is limited because of the difficulties of analytically quantifying food folate content (44) . Errors in the USDA nutrient database for folate (45) may have resulted in misclassification of dietary folate status leading to bias toward the null value. Such bias may explain why a protective association between dietary folate intake from food sources and HPV persistence was not observed. Similarly, RBC folate is a more precise measure of long-term circulating folate levels, whereas serum and plasma are more variable based on recent dietary intake (46) . Although RBC folate was not assessed, the influence of participants’ most recent meal on circulating folate concentrations was minimized by collecting blood samples from fasting participants.

In conclusion, results from this study indicate that elevated circulating levels of vitamin B12 reduce the risk of HPV persistence. Although these findings suggest a role for vitamin B12 in preventing cervical carcinogenic events, larger studies using multiple measures over time need to be conducted to further investigate this relationship.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Supported in part by Arizona Disease Control Research Commission grants (contracts 9710 and 10004). Dr. Sedjo was supported by a National Cancer Institute Pre-Doctoral Cancer Prevention Fellowship (R25-CA78447). Dr. Giuliano was supported in part by a National Cancer Institute Career Development Award (K07-CA60885).

  • ↵2 To whom requests for reprints should be addressed, at Arizona Cancer Center, 1515 N. Campbell Avenue, Room 4977 C, Tucson, AZ 85724-5024. Phone: (520) 626-3341; Fax: (520) 626-3343; E-mail: agiuliano{at}azcc.arizona.edu

  • ↵3 The abbreviations used are: HPV, human papillomavirus; RLU, relative light unit; AFFQ, Arizona Food Frequency Questionnaire; USDA, United States Dietary Association; BMI, body mass index; CI, confidence interval; OR, odds ratio.

  • Received August 24, 2001.
  • Revision received January 11, 2002.
  • Accepted January 23, 2002.

References

  1. ↵
    Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer, 80: 827-841, 1999.
    OpenUrlCrossRefPubMed
  2. ↵
    Franco E. L. Epidemiology of anogenital warts and cancer. Obstet. Gynecol. Clin. North Am., 23: 597-623, 1996.
    OpenUrlPubMed
  3. ↵
    Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J., Peto J., Meijer C. J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19, 1999.
    OpenUrlCrossRefPubMed
  4. ↵
    Bosch F. X., Manos M. M., Munoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J. Natl. Cancer Inst. (Bethesda), 87: 796-802, 1995.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. (Bethesda), 87: 1365-1371, 1995.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med., 338: 423-428, 1998.
    OpenUrlCrossRefPubMed
  7. ↵
    Ho G. Y., Palan P. R., Basu J., Romney S. L., Kadish A. S., Mikhail M., Wassertheil-Smoller S., Runowicz C., Burk R. D. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int. J. Cancer, 78: 594-599, 1998.
    OpenUrlCrossRefPubMed
  8. ↵
    Wheeler C. M., Greer C. E., Becker T. M., Hunt W. C., Anderson S. M., Manos M. M. Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet. Gynecol., 88: 261-268, 1996.
    OpenUrlCrossRefPubMed
  9. ↵
    Moscicki A. B., Palefsky J., Smith G., Siboshski S., Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet. Gynecol., 82: 578-585, 1993.
    OpenUrlPubMed
  10. ↵
    Koutsky L. A., Holmes K. K., Critchlow C. W., Stevens C. E., Paavonen J., Beckmann A. M., DeRouen T. A., Galloway D. A., Vernon D., Kiviat N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278, 1992.
    OpenUrlCrossRefPubMed
  11. ↵
    Moscicki A. B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., Miller S., Clayton L., Farhat S., Broering J., Darragh T., Palefsky J. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA, 285: 2995-3002, 2001.
    OpenUrlCrossRefPubMed
  12. ↵
    Potischman N., Brinton L. A. Nutrition and cervical neoplasia. Cancer Causes Control, 7: 113-126, 1996.
    OpenUrlCrossRefPubMed
  13. ↵
    Rosl F., Schwarz E. Regulation of E6 and E7 oncogenic transcription Tommasino M. eds. . Papillomaviruses in Human Cancer: Role of E6 and E7 Oncoproteins, 25-70, Landes Bioscience and Chapmena & Hall Austin, Texas 1997.
  14. ↵
    Rosl F., Arab A., Klevenz B., zur Hausen H. The effect of DNA methylation on gene regulation of human papillomaviruses. J. Gen. Virol., 74: 791-801, 1993.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Bailey L. B., Gregory J. F., III Folate metabolism and requirements. J. Nutr., 129: 779-782, 1999.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Choi S. W., Mason J. B. Folate and carcinogenesis: an integrated scheme. J. Nutr., 130: 129-132, 2000.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Selhub J., Miller J. W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am. J. Clin. Nutr., 55: 131-138, 1992.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    VanEenwyk J., Davis F. G., Colman N. Folate, vitamin C, and cervical intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev., 1: 119-124, 1992.
    OpenUrlAbstract
  19. ↵
    Liu T., Soong S. J., Wilson N. P., Craig C. B., Cole P., Macaluso M., Butterworth C. E., Jr. A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol. Biomarkers Prev., 2: 525-530, 1993.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Kanetsky P. A., Gammon M. D., Mandelblatt J., Zhang Z. F., Ramsey E., Dnistrian A., Norkus E. P., Wright T. C., Jr. Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. Nutr. Cancer, 31: 31-40, 1998.
    OpenUrlPubMed
  21. ↵
    Wideroff L., Potischman N., Glass A. G., Greer C. E., Manos M. M., Scott D. R., Burk R. D., Sherman M. E., Wacholder S., Schiffman M. A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix. Nutr. Cancer, 30: 130-136, 1998.
    OpenUrlCrossRefPubMed
  22. ↵
    Ziegler R. G., Jones C. J., Brinton L. A., Norman S. A., Mallin K., Levine R. S., Lehman H. F., Hamman R. F., Trumble A. C., Rosenthal J. F., et al Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Causes Control, 2: 17-29, 1991.
    OpenUrlPubMed
  23. ↵
    Brock K. E., Berry G., Mock P. A., MacLennan R., Truswell A. S., Brinton L. A. Nutrients in diet and plasma and risk of in situ cervical cancer. J. Natl. Cancer Inst. (Bethesda), 80: 580-585, 1988.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Ziegler R. G., Brinton L. A., Hamman R. F., Lehman H. F., Levine R. S., Mallin K., Norman S. A., Rosenthal J. F., Trumble A. C., Hoover R. N. Diet and the risk of invasive cervical cancer among white women in the United States. Am. J. Epidemiol., 132: 432-445, 1990.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Verreault R., Chu J., Mandelson M., Shy K. A case-control study of diet and invasive cervical cancer. Int. J. Cancer, 43: 1050-1054, 1989.
    OpenUrlPubMed
  26. ↵
    Herrero R., Potischman N., Brinton L. A., Reeves W. C., Brenes M. M., Tenorio F., de Britton R. C., Gaitan E. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicators. Am. J. Epidemiol., 134: 1335-1346, 1991.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Kwasniewska A., Tukendorf A., Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. Eur. J. Gynaecol. Oncol., 18: 526-530, 1997.
    OpenUrlPubMed
  28. ↵
    Goodman M. T., McDuffie K., Hernandez B., Wilkens L. R., Selhub J. Case-control study of plasma folate, homocysteine, vitamin b(12), and cysteine as markers of cervical dysplasia. Cancer (Phila.), 89: 376-382, 2000.
    OpenUrlCrossRefPubMed
  29. ↵
    Butterworth C. E., Jr., Hatch K. D., Macaluso M., Cole P., Sauberlich H. E., Soong S. J., Borst M., Baker V. V. Folate deficiency and cervical dysplasia. JAMA, 267: 528-533, 1992.
    OpenUrlCrossRefPubMed
  30. ↵
    Alberg A. J., Selhub J., Shah K. V., Viscidi R. P., Comstock G. W., Helzlsouer K. J. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12, and homocysteine. Cancer Epidemiol. Biomarkers Prev., 9: 761-764, 2000.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Weinstein S. J., Ziegler R. G., Frongillo E. A., Jr., Colman N., Sauberlich H. E., Brinton L. A., Hamman R. F., Levine R. S., Mallin K., Stolley P. D., Bisogni C. A. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U. S. women. J. Nutr., 131: 2040-2048, 2001.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Potischman N., Brinton L. A., Laiming V. A., Reeves W. C., Brenes M. M., Herrero R., Tenorio F., de Britton R. C., Gaitan E. A case-control study of serum folate levels and invasive cervical cancer. Cancer Res., 51: 4785-4789, 1991.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Butterworth C. E., Jr., Hatch K. D., Gore H., Mueller H., Krumdieck C. L. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am. J. Clin. Nutr., 35: 73-82, 1982.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Butterworth C. E., Jr., Hatch K. D., Soong S. J., Cole P., Tamura T., Sauberlich H. E., Borst M., Macaluso M., Baker V. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am. J. Obstet. Gynecol., 166: 803-809, 1992.
    OpenUrlPubMed
  35. ↵
    Childers J. M., Chu J., Voigt L. F., Feigl P., Tamimi H. K., Franklin E. W., Alberts D. S., Meyskens F. L., Jr. Chemoprevention of cervical cancer with folic acid: a phase III southwest oncology group intergroup study. Cancer Epidemiol. Biomarkers Prev., 4: 155-159, 1995.
    OpenUrlAbstract
  36. ↵
    Lorincz A. T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens. Papillomavirus Rep., 7: 1-5, 1996.
  37. ↵
    Block G., Hartman A. M., Dresser C. M., Carroll M. D., Gannon J., Gardner L. A data-based approach to diet questionnaire design and testing. Am. J. Epidemiol., 124: 453-469, 1986.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Thomson, C. A., Giuliano, A. R., Graver, E., Hartz, V., Whitacre, R., Pierce, J., and Marshall, J. R. Reproducibility and validity of the Arizona Cancer Center food frequency questionnaire (AFFQ) among WHEL cohort participants. 25th Annual ASPO Meeting, New York, New York, 2001.
  39. ↵
    Martinez M. E., Marshall J. R., Graver E., Whitacre R. C., Woolf K., Ritenbaugh C., Alberts D. S. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol. Biomarkers Prev., 8: 941-946, 1999.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register, 61: 8781-8797, 1996.
    OpenUrl
  41. ↵
    Kim Y. I. Folate and carcinogenesis: evidence, mechanisms, and implications. J. Nutr. Biochem., 10: 66-88, 1999.
    OpenUrlCrossRefPubMed
  42. ↵
    Kim Y. I., Baik H. W., Fawaz K., Knox T., Lee Y. M., Norton R., Libby E., Mason J. B. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. Am. J. Gastroenterol., 96: 184-195, 2001.
    OpenUrlCrossRefPubMed
  43. ↵
    Green T. J., Allen O. B., O’Connor D. L. A three-day weighed food record and a semiquantitative food-frequency questionnaire are valid measures for assessing the folate and vitamin B-12 intakes of women aged 16 to 19 years. J. Nutr., 128: 1665-1671, 1998.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Subar A. F., Block G., James L. D. Folate intake and food sources in the U. S. population. Am. J. Clin. Nutr., 50: 508-516, 1989.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Gregory J. F., III Case study: folate bioavailability. J. Nutr., 131 (4 Suppl.): 1376S-1382S, 2001.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Senti F. R., Pilch S. M. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). J. Nutr., 115: 1398-1402, 1985.
PreviousNext
Back to top
April 2002
Volume 11, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women
Rebecca L. Sedjo, Paula Inserra, Martha Abrahamsen, Robin B. Harris, Denise J. Roe, Susie Baldwin and Anna R. Giuliano
Cancer Epidemiol Biomarkers Prev April 1 2002 (11) (4) 353-359;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human Papillomavirus Persistence and Nutrients Involved in the Methylation Pathway among a Cohort of Young Women
Rebecca L. Sedjo, Paula Inserra, Martha Abrahamsen, Robin B. Harris, Denise J. Roe, Susie Baldwin and Anna R. Giuliano
Cancer Epidemiol Biomarkers Prev April 1 2002 (11) (4) 353-359;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Estimated Effects of Multi-Cancer Screening
  • Gene–Environment Interaction Portfolio Analysis
  • Risk Prediction for Renal Cell Carcinoma
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement